WO2024055893A1 - Preparation method for bionic multi-component fiber carrying seed cells, and application thereof - Google Patents
Preparation method for bionic multi-component fiber carrying seed cells, and application thereof Download PDFInfo
- Publication number
- WO2024055893A1 WO2024055893A1 PCT/CN2023/117476 CN2023117476W WO2024055893A1 WO 2024055893 A1 WO2024055893 A1 WO 2024055893A1 CN 2023117476 W CN2023117476 W CN 2023117476W WO 2024055893 A1 WO2024055893 A1 WO 2024055893A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tube
- solution
- iii
- phase solution
- deionized water
- Prior art date
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000011664 nicotinic acid Substances 0.000 title abstract description 11
- 239000000243 solution Substances 0.000 claims abstract description 100
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 24
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 24
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 24
- 239000000661 sodium alginate Substances 0.000 claims abstract description 24
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008367 deionised water Substances 0.000 claims abstract description 23
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 23
- 239000001110 calcium chloride Substances 0.000 claims abstract description 19
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 19
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 9
- 239000000648 calcium alginate Substances 0.000 claims abstract description 9
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 9
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 9
- 239000012510 hollow fiber Substances 0.000 claims description 25
- 210000004185 liver Anatomy 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000011521 glass Substances 0.000 claims description 16
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 15
- 230000003592 biomimetic effect Effects 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- SLYCYWCVSGPDFR-UHFFFAOYSA-N octadecyltrimethoxysilane Chemical compound CCCCCCCCCCCCCCCCCC[Si](OC)(OC)OC SLYCYWCVSGPDFR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 241001474374 Blennius Species 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 238000004506 ultrasonic cleaning Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 34
- 229920002451 polyvinyl alcohol Polymers 0.000 description 11
- 238000001035 drying Methods 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000010334 End Stage Liver Disease Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000011444 chronic liver failure Diseases 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/08—Addition of substances to the spinning solution or to the melt for forming hollow filaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/24—Formation of filaments, threads, or the like with a hollow structure; Spinnerette packs therefor
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/10—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one other macromolecular compound obtained by reactions only involving carbon-to-carbon unsaturated bonds as constituent
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/18—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from other substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/28—Materials or treatment for tissue regeneration for liver reconstruction
Definitions
- the invention relates to the field of biomedical materials, and in particular to a preparation method and application of a bionic seed cell-carrying multi-component fiber.
- Liver transplantation is the most effective method to treat severe liver failure, but the problem of insufficient liver donors has seriously affected the widespread implementation of liver transplantation. Finding a safe and effective treatment method for liver failure is a current medical research hotspot and a major issue that needs to be solved urgently.
- bioartificial liver combines biology and engineering. Its principle is to build a three-dimensional space complex of cells and biomaterials as a bioreactor to simulate normal liver function and perform blood circulation outside the body to treat patients with liver failure. Purpose of treatment. This therapy is expected to become an alternative treatment for acute and chronic liver failure, end-stage liver disease and metabolic disorders after liver transplantation, and has broad clinical application prospects.
- Microfluidic technology creates an exciting route towards the preparation of functional materials.
- Microfluidic technology is a technology that confines minute amounts of liquid in micro-sized microchannels and precisely controls and operates them. Therefore, microfluidic technology has high hopes in the preparation of functional microfibers.
- the present invention provides a method for preparing biomimetic seed cell-laden multi-component fibers based on microfluidic technology.
- the purpose of the present invention is to provide a method for preparing bionic seed cell-laden multi-component fibers to promote the proliferation and adhesion of seed cells.
- a method for preparing biomimetic seed cell-laden multi-component fibers including the following steps:
- the IV tube is used as the internal phase solution channel
- the I tube is the intermediate phase solution channel
- the gap between the II tube and the III tube is the external phase solution channel
- the PVA (polyvinyl alcohol) solution is used as the internal phase solution
- the seed cells are loaded Sodium alginate solution is the intermediate phase solution
- calcium chloride aqueous solution is the external phase solution
- step S1 after the preparation of tubes I and II, they are placed in ethanol for ultrasonic cleaning for 5 minutes, and then dried with nitrogen.
- step S1 the prepared II tube is immersed in an acetone solution containing 5% octadecyltrimethoxysilane. Hydrophobic treatment in liquid.
- step S2 the needle is connected to the I tube, III tube, and IV tube through the PE tube.
- step S3 the concentration of the PVA solution is 10 wt%, the concentration of the sodium alginate solution is 2 wt%, and the concentration of the calcium chloride aqueous solution is 1.5 wt%.
- step S3 the flow rates of the internal phase solution, the intermediate phase solution, and the external phase solution are 0.5 mL/h, 3 mL/h, and 10 mL/h respectively.
- step S3 the multi-component hollow fiber device is removed by: first stopping the flow of calcium chloride aqueous solution, then feeding deionized water into the external phase solution channel, and then stopping the flow of sodium alginate solution. After the sodium alginate solution no longer flows out of the tube outlet, stop passing deionized water. Finally, remove the PE tube and needle, and use deionized water to clean each solution channel.
- step S3 the PVA solution, calcium chloride aqueous solution carrying seed cells, and sodium alginate solution were injected into the internal phase solution channel, the external phase solution channel, and the intermediate phase using 1mL, 10mL, and 25mL SGE precision syringes to remove bubbles respectively. solution channel.
- the invention also provides a biomimetic seed cell-laden multicomponent fiber obtained by any of the above preparation methods and its application in preparing a bioartificial liver.
- the present invention builds a multi-component hollow fiber device with multi-phase solution channels that is easy to accurately control and operate by drawing and assembling several glass capillary tubes and installing needles through PE tubes; PVA solution, sodium alginate solution, and calcium chloride aqueous solution carrying seed cells are introduced into the channel and the external phase solution channel, relying on the reaction of sodium alginate and calcium chloride solution that can quickly form ultrafine fiber gel to promote seed cells For proliferation and adhesion, biomimetic seed cell-laden multi-component hollow fibers were prepared by adjusting the flow rates of the three solutions.
- the prepared bionic seed cell-laden multi-component (hollow) fiber has high biocompatibility and can maintain the morphology and function of liver cells for a period of time; it also has a similar structure to the natural liver lobule and is multi-component hollow.
- the fiber has a bionic bile canalicular structure, which is conducive to material transport and function.
- Figure 1 is a schematic structural diagram of a multi-component hollow fiber device
- Figure 2 is a physical diagram of the multi-component hollow fiber device
- Figure 3 shows the fluorescence microscope images of the cross-section and longitudinal section of the prepared multi-component fiber (non-hollow), (a) is the cross-section, (b) is the longitudinal section;
- Figure 4 is a cross-sectional fluorescence microscope image of the prepared multi-component hollow fiber with bionic seed cells for bioartificial liver;
- Figure 5 is a scanning electron microscope image of the prepared multi-component hollow fiber with bionic seed cells for bioartificial liver
- Figure 6 is a fluorescent image of live and dead staining of the prepared bioartificial liver after culture with multi-component hollow fibers of bionic seed cells;
- Figure 7 is a schematic diagram of albumin and urea secretion after co-culture of bionic seed cell-laden multi-component fibers and bionic seed cell-laden multi-component hollow fibers.
- Multi-component hollow fibers are prepared by the following method, specifically including the following steps:
- tube II Draw a glass capillary tube with an inner diameter larger than the tip end of tube I, and gently polish any port on sandpaper until the port is flat and smooth to obtain tube II; tube I and tube II are placed in ethanol after preparation Ultrasonically clean for 5 minutes, blow dry with nitrogen, and immerse the prepared II tube in an acetone solution containing 5% octadecyltrimethoxysilane for hydrophobic treatment;
- tube IV as the internal phase solution channel
- tube I as the intermediate phase solution channel
- the gap between tube II and tube III as the external phase solution channel
- 10wt% PVA solution as the internal phase solution
- 2wt% seed cells The sodium alginate solution is the intermediate phase solution
- the 1.5wt% calcium chloride aqueous solution is the external phase solution;
- the diameter of the jet gradually increases; after the jet stabilizes, the seeded cells begin to flow at a flow rate of 3mL/h. of sodium alginate solution. After a few minutes, gradually introduce the calcium chloride aqueous solution into the external phase solution channel. At the same time, reduce the flow rate of the deionized water to ensure that the linear jet flow flows out stably until the deionized water is no longer introduced and the chlorine The flow rate of the calcium chloride aqueous solution is 10ml/L. At this time, the linear jet flow is completely transformed into a gel-like calcium alginate fiber, which flows along the outlet channel driven by the calcium chloride aqueous solution; it is collected and prepared using the calcium chloride solution. of calcium alginate fiber;
- Multi-component hollow fibers loaded with seed cells were then prepared according to the method of Example 1, and multi-component hollow fibers loaded with seed cells (non-hollow) were prepared according to a method similar to Example 1 (the only difference being that the PVA solution was not passed through).
- the sodium alginate solution loaded with seed cells that flows into the I tube is a sodium alginate solution loaded with seed cells mixed with red and green fluorescent nanoparticles, that is, each of the six parallel tube openings is cross-introduced with red and green fluorescent nanoparticles. Fluorescent nanoparticles were loaded onto the seeded cells in an alginate solution to characterize the different components.
- Figure 3 shows the cross-section and longitudinal sections of the prepared multi-component fiber. Light microscope image, Figure 4 is a cross-sectional fluorescence microscope image of the prepared multi-component hollow fiber, and Figure 5 is a scanning electron microscope image of the multi-component hollow fiber.
- the albumin secretion level and urea synthesis value of HepG2 showed an increasing trend.
- the introduction of PVA solution improves the biological activity of calcium alginate fiber, provides a better environment for cell growth, and thereby promotes functional expression.
Abstract
A preparation method for a bionic multi-component fiber carrying seed cells, and an application thereof. The preparation method comprises the following steps: S1, 1) drawing and assembling tubes I with pointed ends; 2) drawing a tube II having a pointed end; and 3) drawing a tube III having an inner diameter greater than those of the tube I and the tube II; and inserting the tube I and the tube II into the tube III through two openings of the tube III, respectively, inserting the pointed ends of the tubes I into a non-pointed end of the tube II, adjusting the axes of the tubes I, the tube II and the tube III to make same coincide, and fixing the tubes I, the tube II and the tube III in place; S2, drawing a tube IV with a pointed end, coaxially nesting the pointed ends of the tube IV and tubes I, and installing needles outside the tubes I, the tube III and the tube IV; and S3, 1) defining each solution channel and preparing solutions; introducing deionized water into an external solution channel, then sequentially and correspondingly introducing a PVA solution, a sodium alginate solution and a calcium chloride aqueous solution, and gradually reducing the flow rate of the deionized water until the deionized water is completely cut off, so as to obtain a calcium alginate fiber; and using a calcium chloride solution to collect the calcium alginate fibers.
Description
本发明涉及生物医学材料领域,具体涉及一种仿生载种子细胞多组分纤维的制备方法及应用。The invention relates to the field of biomedical materials, and in particular to a preparation method and application of a bionic seed cell-carrying multi-component fiber.
肝移植是治疗重症肝功能衰竭的最为有效的手段,但供肝不足的问题已严重影响了肝移植的广泛开展。寻求一种安全、有效的肝功能衰竭的治疗方法,是目前医学的研究热点和亟待解决的重大问题。Liver transplantation is the most effective method to treat severe liver failure, but the problem of insufficient liver donors has seriously affected the widespread implementation of liver transplantation. Finding a safe and effective treatment method for liver failure is a current medical research hotspot and a major issue that needs to be solved urgently.
近年来,生物人工肝的出现为解决这一难题带来了希望。生物人工肝结合了生物学和工程学,其原理是通过建立一个细胞与生物材料的三维空间复合体作为生物反应器,模拟正常的肝脏功能,在体外进行血液循环,起到对肝功能衰竭患者进行治疗的目的。该疗法有望成为继肝移植后,治疗急、慢性肝功能衰竭、终末期肝病和代谢障碍性疾病的替代治疗手段,具有广阔的临床应用前景。In recent years, the emergence of bioartificial livers has brought hope to solve this problem. The bioartificial liver combines biology and engineering. Its principle is to build a three-dimensional space complex of cells and biomaterials as a bioreactor to simulate normal liver function and perform blood circulation outside the body to treat patients with liver failure. Purpose of treatment. This therapy is expected to become an alternative treatment for acute and chronic liver failure, end-stage liver disease and metabolic disorders after liver transplantation, and has broad clinical application prospects.
众所周知,体外培养的肝细胞之所以很难存活,很大程度上是由于脱离了体内的微环境。因此,要想维持细胞的活性和功能,非常重要的一点就是要尽可能地模拟细胞在体内的微环境,这也是目前构建组织工程肝脏的一个共识和努力方向。如何模拟肝脏天然的肝小叶结构来实现完美的物质输送和功能发挥是一个亟待解决的问题,这就提示我们要从肝小叶管道结构方面来模拟肝脏的微环境。微流控技术创造了一条通向制备功能性材料的令人兴奋的途径。微流控技术是一门将微量液体约束在微尺寸的微通道中并对其进行精确控制及操作的技术。因此,在功能性微纤维制备方面,微流控技术被寄子厚望。As we all know, the reason why hepatocytes cultured in vitro is difficult to survive is largely due to the fact that they are separated from the microenvironment in the body. Therefore, in order to maintain the activity and function of cells, it is very important to simulate the microenvironment of cells in the body as much as possible. This is also the current consensus and direction of efforts to construct tissue-engineered livers. How to simulate the natural hepatic lobular structure of the liver to achieve perfect material transport and function is an urgent problem that needs to be solved. This prompts us to simulate the liver microenvironment from the perspective of the hepatic lobular duct structure. Microfluidic technology creates an exciting route towards the preparation of functional materials. Microfluidic technology is a technology that confines minute amounts of liquid in micro-sized microchannels and precisely controls and operates them. Therefore, microfluidic technology has high hopes in the preparation of functional microfibers.
因此,本发明提供一种基于微流控技术的仿生载种子细胞多组分纤维的制备方法。Therefore, the present invention provides a method for preparing biomimetic seed cell-laden multi-component fibers based on microfluidic technology.
发明内容Contents of the invention
本发明的目的在于提供一种仿生载种子细胞多组分纤维制备方法,以促进种子细胞的增殖和黏附。The purpose of the present invention is to provide a method for preparing bionic seed cell-laden multi-component fibers to promote the proliferation and adhesion of seed cells.
为实现上述目的,本发明采用以下技术方案:In order to achieve the above objects, the present invention adopts the following technical solutions:
一种仿生载种子细胞多组分纤维的制备方法,包括以下步骤:
A method for preparing biomimetic seed cell-laden multi-component fibers, including the following steps:
S1、搭建多组分纤维中空微流控装置S1. Build a multi-component fiber hollow microfluidic device
1)拉制若干根一端具有尖口端的玻璃毛细管,将尖口端在砂纸上轻轻打磨,直至尖口端平整光滑,将其尖口端用速干胶环绕同一轴心同向固定在一起,得到具有尖口端的I管;1) Draw several glass capillary tubes with a pointed end at one end, gently polish the pointed ends on sandpaper until the pointed ends are flat and smooth, and fix the pointed ends together in the same direction around the same axis with quick-drying glue. , obtaining an I-tube with a pointed end;
2)拉制一根内径大于I管尖口端端口的玻璃毛细管,将其任一端口在砂纸上轻轻打磨直至端口平整光滑,得到Ⅱ管;2) Draw a glass capillary tube with an inner diameter larger than the tip end of the I tube, and gently polish any port on sandpaper until the port is flat and smooth to obtain the II tube;
3)将一根尺寸大于I管和Ⅱ管的玻璃毛细管固定在玻璃衬底上,得到Ⅲ管;将I管和Ⅱ管分别从Ⅲ管的两个开口插入,且I管的尖口端部分插入Ⅱ管被砂纸打磨过的一端中,调节I管、Ⅱ管、Ⅲ管的轴心重合后,使用速干胶固定住I管、Ⅱ管、Ⅲ管的位置;3) Fix a glass capillary tube larger than the I tube and II tube on the glass substrate to obtain the III tube; insert the I tube and II tube from the two openings of the III tube respectively, and the tip end of the I tube Insert the end of tube II that has been polished with sandpaper. After adjusting the axes of tube I, tube II, and tube III to coincide, use quick-drying glue to fix the positions of tube I, tube II, and tube III;
S2、搭建多组分中空纤维装置S2. Build multi-component hollow fiber device
拉制一根具有尖口端的玻璃毛细管,得到Ⅳ管;将Ⅳ管的尖口端与I管的尖口端同轴嵌套后固定,Ⅳ管嵌套在I管内;在I管、Ⅲ管、Ⅳ管外分别安装针头并用速干胶固定,得到多组分中空纤维装置;Draw a glass capillary tube with a pointed end to obtain an IV tube; coaxially nest the pointed end of the IV tube with the pointed end of the I tube and fix it. The IV tube is nested in the I tube; between the I tube and III tube , and IV tubes are installed with needles respectively and fixed with quick-drying glue to obtain a multi-component hollow fiber device;
S3、制备纤维S3. Preparation of fiber
1)以Ⅳ管为内相溶液通道、I管为中间相溶液通道、Ⅱ管和Ⅲ管之间的间隙为外相溶液通道,以PVA(聚乙烯醇)溶液为内相溶液、搭载种子细胞的海藻酸钠溶液为中间相溶液、氯化钙水溶液为外相溶液;1) The IV tube is used as the internal phase solution channel, the I tube is the intermediate phase solution channel, the gap between the II tube and the III tube is the external phase solution channel, the PVA (polyvinyl alcohol) solution is used as the internal phase solution, and the seed cells are loaded Sodium alginate solution is the intermediate phase solution, and calcium chloride aqueous solution is the external phase solution;
2)向外相溶液通道中通入去离子水,待去离子水流相稳定后,依次向内相溶液通道、中间相溶液通道、外相溶液通道中分别通入对应的PVA溶液、搭载种子细胞的海藻酸钠溶液、氯化钙水溶液,并逐渐减小去离子水的流速直至完全关闭,制备得到海藻酸钙纤维;使用氯化钙溶液收集制备得到的海藻酸钙纤维后,撤除多组分中空纤维装置。2) Pour deionized water into the external phase solution channel. After the phase of the deionized water flow is stable, sequentially introduce the corresponding PVA solution and seaweed carrying seed cells into the internal phase solution channel, the intermediate phase solution channel, and the external phase solution channel. sodium acid solution, calcium chloride aqueous solution, and gradually reduce the flow rate of deionized water until it is completely shut down to prepare calcium alginate fiber; after using the calcium chloride solution to collect the prepared calcium alginate fiber, remove the multi-component hollow fiber device.
当装置内出现流体紊乱或堵塞现象时,迅速停止通入氯化钙,通入并增大去离子水流流速至10mL/h以上。When fluid disorder or blockage occurs in the device, quickly stop the flow of calcium chloride, and increase the flow rate of deionized water to more than 10 mL/h.
为优化上述技术方案,采取的具体措施还包括:In order to optimize the above technical solutions, specific measures taken also include:
进一步地,步骤S1中,I管、Ⅱ管制备完成后置于乙醇中超声清洗5分钟,氮气吹干。Further, in step S1, after the preparation of tubes I and II, they are placed in ethanol for ultrasonic cleaning for 5 minutes, and then dried with nitrogen.
进一步地,步骤S1中,制备得到的Ⅱ管浸没于含有5%十八烷基三甲氧基硅烷的丙酮溶
液中进行疏水处理。Further, in step S1, the prepared II tube is immersed in an acetone solution containing 5% octadecyltrimethoxysilane. Hydrophobic treatment in liquid.
进一步地,步骤S2中,针头通过PE管和I管、Ⅲ管、Ⅳ管连通。Further, in step S2, the needle is connected to the I tube, III tube, and IV tube through the PE tube.
进一步地,步骤S3中,PVA溶液的浓度为10wt%、海藻酸钠溶液的浓度为2wt%、氯化钙水溶液的浓度为1.5wt%。Further, in step S3, the concentration of the PVA solution is 10 wt%, the concentration of the sodium alginate solution is 2 wt%, and the concentration of the calcium chloride aqueous solution is 1.5 wt%.
进一步地,步骤S3中,内相溶液、中间相溶液、外相溶液的流速分别为0.5mL/h、3mL/h、10mL/h。Further, in step S3, the flow rates of the internal phase solution, the intermediate phase solution, and the external phase solution are 0.5 mL/h, 3 mL/h, and 10 mL/h respectively.
进一步地,步骤S3中,多组分中空纤维装置撤除的方式为:先停止通入氯化钙水溶液,然后向外相溶液通道中通入去离子水,之后停止通入海藻酸钠溶液,在I管出口不再有海藻酸钠溶液流出后,停止通入去离子水,最后拆除PE管和针头,使用去离子水清洗各溶液通道。Further, in step S3, the multi-component hollow fiber device is removed by: first stopping the flow of calcium chloride aqueous solution, then feeding deionized water into the external phase solution channel, and then stopping the flow of sodium alginate solution. After the sodium alginate solution no longer flows out of the tube outlet, stop passing deionized water. Finally, remove the PE tube and needle, and use deionized water to clean each solution channel.
进一步地,步骤S3中,PVA溶液、搭载种子细胞的氯化钙水溶液、海藻酸钠溶液分别用1mL、10mL和25mL的SGE精密注射器去除气泡后注射进内相溶液通道、外相溶液通道、中间相溶液通道。Further, in step S3, the PVA solution, calcium chloride aqueous solution carrying seed cells, and sodium alginate solution were injected into the internal phase solution channel, the external phase solution channel, and the intermediate phase using 1mL, 10mL, and 25mL SGE precision syringes to remove bubbles respectively. solution channel.
本发明还提供一种通过上述任一项制备方法得到的仿生载种子细胞多组分纤维及其在制备生物人工肝中的应用。The invention also provides a biomimetic seed cell-laden multicomponent fiber obtained by any of the above preparation methods and its application in preparing a bioartificial liver.
本发明的有益效果是:The beneficial effects of the present invention are:
本发明通过拉制、组装若干玻璃毛细管并通过PE管安装针头,搭建了一种便于精确控制和操作的具有多相溶液通道的多组分中空纤维装置;分别向内相溶液通道、中间相溶液通道、外相溶液通道中通入PVA溶液、搭载种子细胞的海藻酸钠溶液、氯化钙水溶液,依赖于能够快速形成超细纤维凝胶的海藻酸钠与氯化钙溶液的反应,促进种子细胞的增殖和黏附,通过调节三者溶液的流速制备了仿生载种子细胞多组分中空纤维。制备得到的仿生载种子细胞多组分(中空)纤维具有较高的生物相容性,能在一段时间内维持肝细胞的形态和功能;其还与天然肝小叶结构相似,且多组分中空纤维具有仿生胆小管结构,有利于实现的物质输送和功能发挥。以上优点证明了本发明制备的纤维在制备生物人工肝中具有潜在的应用价值。The present invention builds a multi-component hollow fiber device with multi-phase solution channels that is easy to accurately control and operate by drawing and assembling several glass capillary tubes and installing needles through PE tubes; PVA solution, sodium alginate solution, and calcium chloride aqueous solution carrying seed cells are introduced into the channel and the external phase solution channel, relying on the reaction of sodium alginate and calcium chloride solution that can quickly form ultrafine fiber gel to promote seed cells For proliferation and adhesion, biomimetic seed cell-laden multi-component hollow fibers were prepared by adjusting the flow rates of the three solutions. The prepared bionic seed cell-laden multi-component (hollow) fiber has high biocompatibility and can maintain the morphology and function of liver cells for a period of time; it also has a similar structure to the natural liver lobule and is multi-component hollow. The fiber has a bionic bile canalicular structure, which is conducive to material transport and function. The above advantages prove that the fiber prepared by the present invention has potential application value in preparing bioartificial liver.
图1为多组分中空纤维装置结构示意图;Figure 1 is a schematic structural diagram of a multi-component hollow fiber device;
图2为多组分中空纤维装置的实物图;
Figure 2 is a physical diagram of the multi-component hollow fiber device;
图3为制备的多组分纤维(非中空)的横截面和纵截面荧光显微镜图像,(a)为横截面,(b)为纵截面;Figure 3 shows the fluorescence microscope images of the cross-section and longitudinal section of the prepared multi-component fiber (non-hollow), (a) is the cross-section, (b) is the longitudinal section;
图4为制备的生物人工肝用仿生载种子细胞多组分中空纤维的横截面荧光显微镜图像;Figure 4 is a cross-sectional fluorescence microscope image of the prepared multi-component hollow fiber with bionic seed cells for bioartificial liver;
图5为制备的生物人工肝用仿生载种子细胞多组分中空纤维的扫描电镜图像;Figure 5 is a scanning electron microscope image of the prepared multi-component hollow fiber with bionic seed cells for bioartificial liver;
图6为制备的生物人工肝用仿生载种子细胞多组分中空纤维培养后的活死染色的荧光图像;Figure 6 is a fluorescent image of live and dead staining of the prepared bioartificial liver after culture with multi-component hollow fibers of bionic seed cells;
图7为仿生载种子细胞多组分纤维与仿生载种子细胞多组分中空纤维共培养后白蛋白与尿素分泌示意图。Figure 7 is a schematic diagram of albumin and urea secretion after co-culture of bionic seed cell-laden multi-component fibers and bionic seed cell-laden multi-component hollow fibers.
实施例1制备多组分中空纤维Example 1 Preparation of multi-component hollow fibers
多组分中空纤维通过以下方法制备,具体包括以下步骤:Multi-component hollow fibers are prepared by the following method, specifically including the following steps:
S1、搭建多组分纤维微流控装置S1. Build a multi-component fiber microfluidic device
1)如图1所示,拉制6根一端具有尖口端的玻璃毛细管,将尖口端在砂纸上轻轻打磨,直至尖口端平整光滑,将其尖口端用速干胶环绕同一轴心同向固定在一起,得到具有尖口端的I管;1) As shown in Figure 1, draw 6 glass capillary tubes with a pointed end at one end. Gently polish the pointed ends on sandpaper until the pointed ends are flat and smooth. Wrap the pointed ends around the same axis with quick-drying glue. The hearts are fixed together in the same direction to obtain an I tube with a pointed end;
2)拉制一根内径大于I管尖口端端口的玻璃毛细管,将其任一端口在砂纸上轻轻打磨直至端口平整光滑,得到Ⅱ管;I管、Ⅱ管制备完成后置于乙醇中超声清洗5分钟,氮气吹干,制备得到的Ⅱ管浸没于含有5%十八烷基三甲氧基硅烷的丙酮溶液中进行疏水处理;2) Draw a glass capillary tube with an inner diameter larger than the tip end of tube I, and gently polish any port on sandpaper until the port is flat and smooth to obtain tube II; tube I and tube II are placed in ethanol after preparation Ultrasonically clean for 5 minutes, blow dry with nitrogen, and immerse the prepared II tube in an acetone solution containing 5% octadecyltrimethoxysilane for hydrophobic treatment;
3)将一根尺寸大于I管和Ⅱ管的玻璃毛细管固定在玻璃衬底上,得到Ⅲ管;将I管和Ⅱ管分别从Ⅲ管的两个开口插入,且I管的尖口端部分插入Ⅱ管被砂纸打磨过的一端中,调节I管、Ⅱ管、Ⅲ管的轴心重合后,使用速干胶固定住I管、Ⅱ管、Ⅲ管的位置;3) Fix a glass capillary tube larger than the I tube and II tube on the glass substrate to obtain the III tube; insert the I tube and II tube from the two openings of the III tube respectively, and the tip end of the I tube Insert the end of tube II that has been polished with sandpaper. After adjusting the axes of tube I, tube II, and tube III to coincide, use quick-drying glue to fix the positions of tube I, tube II, and tube III;
S2、搭建多组分中空纤维装置S2. Build multi-component hollow fiber device
拉制一根具有尖口端的玻璃毛细管,得到Ⅳ管;将Ⅳ管的尖口端同轴嵌套在I管的尖口端中;如图2所示,在I管、Ⅲ管、Ⅳ管外分别通过PE管安装针头并用速干胶固定,得到多组分中空纤维装置;
Draw a glass capillary tube with a pointed end to obtain an IV tube; coaxially nest the pointed end of the IV tube in the pointed end of the I tube; as shown in Figure 2, between the I tube, III tube, and IV tube Install needles through PE pipes and fix them with quick-drying glue to obtain a multi-component hollow fiber device;
S3、制备纤维S3. Preparation of fiber
1)以Ⅳ管为内相溶液通道、I管为中间相溶液通道、Ⅱ管和Ⅲ管之间的间隙为外相溶液通道,以10wt%的PVA溶液为内相溶液、2wt%的搭载种子细胞的海藻酸钠溶液为中间相溶液、1.5wt%的氯化钙水溶液为外相溶液;1) Use tube IV as the internal phase solution channel, tube I as the intermediate phase solution channel, the gap between tube II and tube III as the external phase solution channel, use 10wt% PVA solution as the internal phase solution, and 2wt% seed cells. The sodium alginate solution is the intermediate phase solution, and the 1.5wt% calcium chloride aqueous solution is the external phase solution;
2)分别用1mL、10mL和25mL的SGE精密注射器吸取上一步制备的PVA溶液、氯化钙水溶液、搭载种子细胞的海藻酸钠溶液,然后将注射器放置于蠕动泵的卡槽内,设置好型号、量程、流速等参数。首先向外相溶液通道中通入流速为10mL/h的去离子水,待去离子水流体稳定后,以0.5mL/h的流速开始通入PVA溶液,半分钟后,内相溶液通道的出口处出现细长且连续的线状喷射流,随着喷射流逐渐远离内相溶液通道的出口,喷射流的口径逐渐增大;待喷射流稳定后,以3mL/h的流速开始通入搭载种子细胞的海藻酸钠溶液,数分钟后逐渐向外相溶液通道通入氯化钙水溶液,同时减小去离子水的流速,保证线状喷射流一直稳定地流出,直至去离子水不再通入,氯化钙水溶液的流速为10ml/L,此时线状喷射流完全转化为凝胶状的海藻酸钙纤维,在氯化钙水溶液的驱动下沿着出口通道流动;使用氯化钙溶液收集制备得到的海藻酸钙纤维;2) Use 1mL, 10mL and 25mL SGE precision syringes to absorb the PVA solution, calcium chloride aqueous solution and sodium alginate solution prepared in the previous step respectively, then place the syringe in the slot of the peristaltic pump and set the model , measuring range, flow rate and other parameters. First, deionized water with a flow rate of 10mL/h was introduced into the external phase solution channel. After the deionized water fluid stabilized, PVA solution was started to be introduced at a flow rate of 0.5mL/h. After half a minute, the outlet of the internal phase solution channel A slender and continuous linear jet appears. As the jet gradually moves away from the outlet of the internal phase solution channel, the diameter of the jet gradually increases; after the jet stabilizes, the seeded cells begin to flow at a flow rate of 3mL/h. of sodium alginate solution. After a few minutes, gradually introduce the calcium chloride aqueous solution into the external phase solution channel. At the same time, reduce the flow rate of the deionized water to ensure that the linear jet flow flows out stably until the deionized water is no longer introduced and the chlorine The flow rate of the calcium chloride aqueous solution is 10ml/L. At this time, the linear jet flow is completely transformed into a gel-like calcium alginate fiber, which flows along the outlet channel driven by the calcium chloride aqueous solution; it is collected and prepared using the calcium chloride solution. of calcium alginate fiber;
3)制备结束后,先停止通入氯化钙水溶液,然后向外相溶液通道中通入去离子水,之后停止通入搭载种子细胞的海藻酸钠溶液,在I管出口不再有海藻酸钠溶液流出后,停止通入去离子水,最后拆除PE管和针头,使用去离子水清洗各溶液通道。3) After the preparation is completed, first stop feeding the calcium chloride aqueous solution, then pour deionized water into the external phase solution channel, and then stop feeding the sodium alginate solution carrying the seed cells. There will no longer be sodium alginate at the outlet of the I tube. After the solution flows out, stop flowing in deionized water, finally remove the PE tube and needle, and use deionized water to clean each solution channel.
实施例2形态和相容性测试Example 2 Morphology and Compatibility Testing
称取海藻酸钠粉末置于超净台中的紫外灭菌灯下过夜照射后用灭菌水溶解配置,用胰蛋白酶将细胞从培养瓶壁消化下来,转移至离心管中离心,去除胰蛋白酶及旧的培养液加入到无菌海藻酸钠溶液,用移液枪轻轻吹打细胞直至完全悬浮且均匀分散在海藻酸钠溶液中,即得到搭载种子细胞的海藻酸钠溶液。然后按照实施例1的方法制备负载种子细胞的多组分中空纤维,以及按照与实施例1相似的方法(区别仅在于不通入PVA溶液)制备负载种子细胞的多组分纤维(非中空)。Weigh the sodium alginate powder and place it under a UV sterilization lamp in a clean bench overnight, then dissolve it in sterile water and use trypsin to digest the cells from the wall of the culture bottle. Transfer to a centrifuge tube and centrifuge to remove the trypsin and Add the old culture medium to the sterile sodium alginate solution, and gently pipette the cells with a pipette until they are completely suspended and evenly dispersed in the sodium alginate solution, thus obtaining a sodium alginate solution carrying seed cells. Multi-component hollow fibers loaded with seed cells were then prepared according to the method of Example 1, and multi-component hollow fibers loaded with seed cells (non-hollow) were prepared according to a method similar to Example 1 (the only difference being that the PVA solution was not passed through).
其中,通入I管的搭载种子细胞的海藻酸钠溶液为掺有红色和绿色荧光纳米粒子的搭载种子细胞的海藻酸钠溶液,即六口并行的每个管口交叉引入掺有红色和绿色荧光纳米粒子的搭载种子细胞的海藻酸钠溶液,以表征不同的组分。图3为制备的多组分纤维的横截面和纵截面荧
光显微镜图像,图4为制备的多组分中空纤维的横截面荧光显微镜图,图5为多组分中空纤维的扫描电镜图像。Among them, the sodium alginate solution loaded with seed cells that flows into the I tube is a sodium alginate solution loaded with seed cells mixed with red and green fluorescent nanoparticles, that is, each of the six parallel tube openings is cross-introduced with red and green fluorescent nanoparticles. Fluorescent nanoparticles were loaded onto the seeded cells in an alginate solution to characterize the different components. Figure 3 shows the cross-section and longitudinal sections of the prepared multi-component fiber. Light microscope image, Figure 4 is a cross-sectional fluorescence microscope image of the prepared multi-component hollow fiber, and Figure 5 is a scanning electron microscope image of the multi-component hollow fiber.
如图6所示,为了检测细胞在纤维中的生命活性,用Calcein AM和碘化丙啶(PI)对活细胞和死细胞同时进行染色。纤维被染色后大多数细胞呈现绿色,没有细胞被染成红色,说明细胞维持良好的活性,微流控制备的纤维对细胞的损害很小。As shown in Figure 6, in order to detect the vital activity of cells in the fiber, living cells and dead cells were stained simultaneously with Calcein AM and propidium iodide (PI). After the fibers were stained, most of the cells appeared green and no cells were stained red, indicating that the cells maintained good activity and the fibers prepared by microfluidics caused little damage to the cells.
实施例3仿生载种子细胞多组分纤维在制备生物人工肝中的应用Example 3 Application of biomimetic seed cell-loaded multicomponent fibers in the preparation of bioartificial liver
在相同的实验条件下制备多组分纤维、多组分中空纤维,保证上述纤维内包裹的细胞量一致,分别用白蛋白试剂盒和尿素试剂盒测量纤维中HepG2白蛋白分泌水平和尿素合成值这两个重要指标,定量地考察HepG2细胞在具有不同细胞分布结构的三维共培养环境下功能的表达情况。Prepare multi-component fibers and multi-component hollow fibers under the same experimental conditions to ensure that the amount of cells wrapped in the fibers is consistent. Use an albumin kit and a urea kit to measure the HepG2 albumin secretion level and urea synthesis value in the fibers respectively. These two important indicators quantitatively examine the functional expression of HepG2 cells in a three-dimensional co-culture environment with different cell distribution structures.
如图7所示,HepG2的白蛋白分泌水平和尿素合成值都呈增长的趋势。PVA溶液的引入,提高了海藻酸钙纤维的生物活性,为细胞生长提供了更好的环境,进而促进了功能的表达。As shown in Figure 7, the albumin secretion level and urea synthesis value of HepG2 showed an increasing trend. The introduction of PVA solution improves the biological activity of calcium alginate fiber, provides a better environment for cell growth, and thereby promotes functional expression.
以上仅是本发明的优选实施方式,本发明的保护范围并不仅局限于上述实施例,凡属于本发明思路下的技术方案均属于本发明的保护范围。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理前提下的若干改进和润饰,应视为本发明的保护范围。
The above are only preferred embodiments of the present invention. The protection scope of the present invention is not limited to the above-mentioned embodiments. All technical solutions that fall under the idea of the present invention belong to the protection scope of the present invention. It should be pointed out that for those of ordinary skill in the art, several improvements and modifications without departing from the principle of the present invention should be regarded as the protection scope of the present invention.
Claims (10)
- 一种仿生载种子细胞多组分纤维的制备方法,其特征在于,包括以下步骤:A method for preparing biomimetic seed cell-laden multi-component fibers, which is characterized by including the following steps:S1、搭建多组分纤维微流控装置S1. Build a multi-component fiber microfluidic device1)拉制若干根一端具有尖口端的玻璃毛细管,将其尖口端环绕同一轴心同向固定在一起,得到具有尖口端的I管;1) Draw several glass capillary tubes with a pointed end at one end, and fix the pointed ends together in the same direction around the same axis to obtain an I-tube with a pointed end;2)拉制一根内径大于I管尖口端端口的玻璃毛细管,得到Ⅱ管;2) Draw a glass capillary tube with an inner diameter larger than the tip end of the I tube to obtain the II tube;3)将一根尺寸大于I管和Ⅱ管的玻璃毛细管固定在玻璃衬底上,得到Ⅲ管;将I管和Ⅱ管分别从Ⅲ管的两个开口插入,且I管的尖口端部分插入Ⅱ管中,调节I管、Ⅱ管、Ⅲ管的轴心重合后,固定住I管、Ⅱ管、Ⅲ管的位置;3) Fix a glass capillary tube larger than the I tube and II tube on the glass substrate to obtain the III tube; insert the I tube and II tube from the two openings of the III tube respectively, and the tip end of the I tube Insert into tube II, adjust the axes of tube I, tube II, and tube III to coincide, and then fix the positions of tube I, tube II, and tube III;S2、搭建多组分中空纤维装置S2. Build multi-component hollow fiber device拉制一根具有尖口端的玻璃毛细管,得到Ⅳ管;将Ⅳ管的尖口端与I管的尖口端同轴嵌套后固定;在I管、Ⅲ管、Ⅳ管外分别安装针头,得到多组分中空纤维装置;Draw a glass capillary tube with a pointed end to obtain an IV tube; coaxially nest the pointed end of the IV tube and the pointed end of the I tube and fix it; install needles outside the I tube, III tube, and IV tube respectively. A multi-component hollow fiber device is obtained;S3、制备纤维S3. Preparation of fiber1)以Ⅳ管为内相溶液通道、I管为中间相溶液通道、Ⅱ管和Ⅲ管之间的间隙为外相溶液通道,以PVA溶液为内相溶液、搭载种子细胞的海藻酸钠溶液为中间相溶液、氯化钙水溶液为外相溶液;1) The IV tube is the internal phase solution channel, the I tube is the intermediate phase solution channel, the gap between the II tube and the III tube is the external phase solution channel, the PVA solution is the internal phase solution, and the sodium alginate solution carrying seed cells is The intermediate phase solution and calcium chloride aqueous solution are the external phase solutions;2)向外相溶液通道中通入去离子水,待去离子水流相稳定后,依次向内相溶液通道、中间相溶液通道、外相溶液通道中分别通入对应的PVA溶液、搭载种子细胞的海藻酸钠溶液、氯化钙水溶液,并逐渐减小去离子水的流速直至完全关闭,制备得到海藻酸钙纤维;使用氯化钙溶液收集制备得到的海藻酸钙纤维后,撤除多组分中空纤维装置。2) Pour deionized water into the external phase solution channel. After the phase of the deionized water flow is stable, sequentially introduce the corresponding PVA solution and seaweed carrying seed cells into the internal phase solution channel, the intermediate phase solution channel, and the external phase solution channel. sodium acid solution, calcium chloride aqueous solution, and gradually reduce the flow rate of deionized water until it is completely shut down to prepare calcium alginate fiber; after using the calcium chloride solution to collect the prepared calcium alginate fiber, remove the multi-component hollow fiber device.
- 根据权利要求1所述的一种仿生载种子细胞多组分纤维的制备方法,其特征在于,A method for preparing biomimetic seed cell-laden multi-component fibers according to claim 1, characterized in that:步骤S1中,I管、Ⅱ管制备完成后置于乙醇中超声清洗5分钟,氮气吹干。In step S1, after the preparation of tubes I and II, place them in ethanol for ultrasonic cleaning for 5 minutes and blow dry with nitrogen.
- 根据权利要求1所述的一种仿生载种子细胞多组分纤维的制备方法,其特征在于,A method for preparing biomimetic seed cell-laden multi-component fibers according to claim 1, characterized in that,步骤S1中,制备得到的Ⅱ管浸没于含有5%十八烷基三甲氧基硅烷的丙酮溶液中进行疏水处理。In step S1, the prepared II tube is immersed in an acetone solution containing 5% octadecyltrimethoxysilane for hydrophobic treatment.
- 根据权利要求1所述的一种仿生载种子细胞多组分纤维的制备方法,其特征在于,A method for preparing biomimetic seed cell-laden multi-component fibers according to claim 1, characterized in that,步骤S2中,针头通过PE管和I管、Ⅲ管、Ⅳ管连通。In step S2, the needle is connected to the I tube, III tube, and IV tube through the PE tube.
- 根据权利要求1所述的一种仿生载种子细胞多组分纤维的制备方法,其特征在于,A method for preparing biomimetic seed cell-laden multi-component fibers according to claim 1, characterized in that,步骤S3中,PVA溶液的浓度为10wt%、海藻酸钠溶液的浓度为2wt%、氯化钙水溶液的浓度为1.5wt%。 In step S3, the concentration of the PVA solution is 10 wt%, the concentration of the sodium alginate solution is 2 wt%, and the concentration of the calcium chloride aqueous solution is 1.5 wt%.
- 根据权利要求1所述的一种仿生载种子细胞多组分纤维的制备方法,其特征在于,A method for preparing biomimetic seed cell-laden multi-component fibers according to claim 1, characterized in that,步骤S3中,内相溶液、中间相溶液、外相溶液的流速分别为0.5mL/h、3mL/h、10mL/h。In step S3, the flow rates of the internal phase solution, the intermediate phase solution, and the external phase solution are 0.5 mL/h, 3 mL/h, and 10 mL/h respectively.
- 根据权利要求4所述的一种仿生载种子细胞多组分纤维的制备方法,其特征在于,A method for preparing biomimetic seed cell-laden multi-component fibers according to claim 4, characterized in that:步骤S3中,多组分中空纤维装置撤除的方式为:先停止通入氯化钙水溶液,然后向外相溶液通道中通入去离子水,之后停止通入搭载种子细胞的海藻酸钠溶液,在I管出口不再有搭载种子细胞的海藻酸钠溶液流出后,停止通入去离子水,最后拆除PE管和针头,使用去离子水清洗各溶液通道。In step S3, the multi-component hollow fiber device is removed by: first stopping the flow of the calcium chloride aqueous solution, then feeding the deionized water into the external phase solution channel, and then stopping the flow of the sodium alginate solution carrying the seed cells. After the sodium alginate solution carrying seed cells no longer flows out of the outlet of the I tube, stop flowing in deionized water. Finally, remove the PE tube and needle, and use deionized water to clean each solution channel.
- 根据权利要求1所述的一种仿生载种子细胞多组分纤维的制备方法,其特征在于,A method for preparing biomimetic seed cell-laden multi-component fibers according to claim 1, characterized in that,步骤S3中,PVA溶液、氯化钙水溶液、搭载种子细胞的海藻酸钠溶液分别用1mL、10mL和25mL的SGE精密注射器去除气泡后注射进内相溶液通道、外相溶液通道、中间相溶液通道。In step S3, PVA solution, calcium chloride aqueous solution, and sodium alginate solution loaded with seed cells are respectively removed from bubbles with 1mL, 10mL, and 25mL SGE precision syringes and then injected into the internal phase solution channel, external phase solution channel, and intermediate phase solution channel.
- 如权利要求1~8任一项所述制备方法制得的仿生载种子细胞多组分纤维。The biomimetic seed cell-laden multi-component fiber prepared by the preparation method according to any one of claims 1 to 8.
- 如权利要求9所述的仿生载种子细胞多组分纤维在制备生物人工肝中的应用。 Use of the biomimetic seed cell-loaded multicomponent fiber as claimed in claim 9 in the preparation of a bioartificial liver.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211023430.6A CN115262028A (en) | 2022-09-13 | 2022-09-13 | Preparation method and application of bionic seed cell-carrying multi-component fiber |
CN202211023430.6 | 2022-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024055893A1 true WO2024055893A1 (en) | 2024-03-21 |
Family
ID=83753379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/117476 WO2024055893A1 (en) | 2022-09-13 | 2023-09-07 | Preparation method for bionic multi-component fiber carrying seed cells, and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115262028A (en) |
WO (1) | WO2024055893A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115262028A (en) * | 2022-09-13 | 2022-11-01 | 南京鼓楼医院 | Preparation method and application of bionic seed cell-carrying multi-component fiber |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100740169B1 (en) * | 2006-06-28 | 2007-07-16 | 학교법인 포항공과대학교 | Cell containing alginic acid micro-fiber scaffold and fabrication method thereof |
JP2013009598A (en) * | 2011-05-31 | 2013-01-17 | Chiba Univ | Complex type hepatocyte organoid and method for preparing the same |
CN103820880A (en) * | 2014-01-21 | 2014-05-28 | 东南大学 | Calcium alginate fiber and preparation method thereof |
JP2014236698A (en) * | 2013-06-07 | 2014-12-18 | 国立大学法人 鹿児島大学 | Cell aggregate making method |
JP2016077229A (en) * | 2014-10-17 | 2016-05-16 | 国立大学法人 東京大学 | Fiber-like substrate, 3-dimensional cell structure and production method for the same, as well as culture method for 3-dimensional cell structure |
CN106215987A (en) * | 2016-08-12 | 2016-12-14 | 四川大学 | Multichannel also flows micro-fluid chip and the controlled spinning process of linear heterogeneous heterojunction structure fiber based on this chip |
CN108360088A (en) * | 2018-02-28 | 2018-08-03 | 清华大学深圳研究生院 | The method and apparatus for preparing calcium alginate fibre |
CN112921436A (en) * | 2021-03-08 | 2021-06-08 | 南京鼓楼医院 | Fiber wrapping perovskite quantum dots, preparation method and device |
US20210340481A1 (en) * | 2018-08-10 | 2021-11-04 | Mochida Pharmaceutical Co., Ltd. | Alginate hollow microfiber |
CN114457442A (en) * | 2022-01-19 | 2022-05-10 | 西南交通大学 | Spider silk-like hollow spindle knot microfiber device with water collection characteristic and preparation method |
CN114790441A (en) * | 2022-05-07 | 2022-07-26 | 上海大学 | Preparation method of organ chip based on hollow microfibers and organ chip |
CN114854677A (en) * | 2022-07-04 | 2022-08-05 | 南京农业大学 | Microfluidic bionic fiber for cell culture meat production and preparation method and application thereof |
CN115262028A (en) * | 2022-09-13 | 2022-11-01 | 南京鼓楼医院 | Preparation method and application of bionic seed cell-carrying multi-component fiber |
-
2022
- 2022-09-13 CN CN202211023430.6A patent/CN115262028A/en not_active Withdrawn
-
2023
- 2023-09-07 WO PCT/CN2023/117476 patent/WO2024055893A1/en unknown
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100740169B1 (en) * | 2006-06-28 | 2007-07-16 | 학교법인 포항공과대학교 | Cell containing alginic acid micro-fiber scaffold and fabrication method thereof |
JP2013009598A (en) * | 2011-05-31 | 2013-01-17 | Chiba Univ | Complex type hepatocyte organoid and method for preparing the same |
JP2014236698A (en) * | 2013-06-07 | 2014-12-18 | 国立大学法人 鹿児島大学 | Cell aggregate making method |
CN103820880A (en) * | 2014-01-21 | 2014-05-28 | 东南大学 | Calcium alginate fiber and preparation method thereof |
JP2016077229A (en) * | 2014-10-17 | 2016-05-16 | 国立大学法人 東京大学 | Fiber-like substrate, 3-dimensional cell structure and production method for the same, as well as culture method for 3-dimensional cell structure |
CN106215987A (en) * | 2016-08-12 | 2016-12-14 | 四川大学 | Multichannel also flows micro-fluid chip and the controlled spinning process of linear heterogeneous heterojunction structure fiber based on this chip |
CN108360088A (en) * | 2018-02-28 | 2018-08-03 | 清华大学深圳研究生院 | The method and apparatus for preparing calcium alginate fibre |
US20210340481A1 (en) * | 2018-08-10 | 2021-11-04 | Mochida Pharmaceutical Co., Ltd. | Alginate hollow microfiber |
CN112921436A (en) * | 2021-03-08 | 2021-06-08 | 南京鼓楼医院 | Fiber wrapping perovskite quantum dots, preparation method and device |
CN114457442A (en) * | 2022-01-19 | 2022-05-10 | 西南交通大学 | Spider silk-like hollow spindle knot microfiber device with water collection characteristic and preparation method |
CN114790441A (en) * | 2022-05-07 | 2022-07-26 | 上海大学 | Preparation method of organ chip based on hollow microfibers and organ chip |
CN114854677A (en) * | 2022-07-04 | 2022-08-05 | 南京农业大学 | Microfluidic bionic fiber for cell culture meat production and preparation method and application thereof |
CN115262028A (en) * | 2022-09-13 | 2022-11-01 | 南京鼓楼医院 | Preparation method and application of bionic seed cell-carrying multi-component fiber |
Also Published As
Publication number | Publication date |
---|---|
CN115262028A (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2024055893A1 (en) | Preparation method for bionic multi-component fiber carrying seed cells, and application thereof | |
CN105586249B (en) | Circulating perfusion bioreactor device capable of realizing circulating perfusion of three-dimensional support | |
WO2014034146A1 (en) | Cell culture module | |
WO2019147879A2 (en) | Rolled scaffold for large scale cell culture in monolayer | |
JP2014236698A (en) | Cell aggregate making method | |
CN111448305B (en) | Hollow fiber cell culture apparatus, cell culture method, and method for producing culture supernatant | |
JP5727174B2 (en) | Hollow fiber module for cell culture and cell culture method | |
EP3669190B1 (en) | A reliable and reproducible industrialisation process for the elimination of air bubbles in the production of an engineered vascular tissue | |
JP2014060991A (en) | Method of culturing stem cells using inner lumen of porous hollow fiber | |
JP6958350B2 (en) | Method for producing stem cell culture supernatant | |
Chouinard et al. | Design and validation of a pulsatile perfusion bioreactor for 3D high cell density cultures | |
Di Buduo et al. | Three-dimensional tissue models for studying ex vivo megakaryocytopoiesis and platelet production | |
IT201800007946A1 (en) | Model to simulate the behavior of dysfunctional vessels in-vitro | |
JP2017176043A (en) | Cell cultivation using hollow fiber module | |
CN113755425B (en) | Preparation method of porous microcarrier for carrying three-dimensional islet beta cell aggregate | |
JP3726188B2 (en) | Apparatus with hollow fiber and method of using the same | |
US20220251492A1 (en) | Cell culture vessel and cell culture device | |
CN110960732B (en) | Living nerve scaffold with central perfusion system and manufacturing method thereof | |
JP2005110695A (en) | Device comprising hollow fiber and use thereof | |
TWI821230B (en) | Cell culture device, culture medium aspirator and cell culture method | |
JP2019154277A (en) | Cell culture vessel | |
Oh et al. | Microscopic tubular cell organization for artificial vascularization | |
EP4299719A1 (en) | A complex in vitro model of human skin, a process for preparation and use thereof | |
JP2018014947A (en) | Cell culture method using hollow fiber membrane module | |
Tang et al. | Controlled Fabrication of Bioactive Microtubes for Screening Anti-Tongue Squamous Cell Migration Drugs |